Narayan P, Dilawari A, Osgood C, Feng Z, et al. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. J Clin Oncol 2023 Feb 13:JCO2202447. doi: 10.1200/JCO.22.02447.
PMID: 36780610